MetaVia Inc. (NASDAQ:MTVA – Free Report) – Equities research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of MetaVia in a research note issued on Monday, December 30th. HC Wainwright analyst E. Arce expects that the company will post earnings of ($3.87) per share for the year. HC Wainwright currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for MetaVia’s current full-year earnings is ($3.91) per share. HC Wainwright also issued estimates for MetaVia’s Q1 2025 earnings at ($0.65) EPS, Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.73) EPS, Q4 2025 earnings at ($0.65) EPS, FY2027 earnings at ($4.27) EPS and FY2028 earnings at ($4.58) EPS.
MetaVia Stock Up 2.5 %
MTVA stock opened at $2.03 on Tuesday. MetaVia has a twelve month low of $1.51 and a twelve month high of $6.75.
MetaVia Company Profile
MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.
Further Reading
- Five stocks we like better than MetaVia
- Quiet Period Expirations Explained
- Work and Play: Investing in the Rise of Bleisure Travel
- 3 Best Fintech Stocks for a Portfolio Boost
- Top Dividend Stocks to Buy Now as Bond Yields Could Lower
- Bank Stocks – Best Bank Stocks to Invest In
- SAP: AI Tailwinds Accelerating Enterprise Cloud Business
Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.
